Tradestie Institutional Equity Comparison Engine
ICCC vs IMMX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ICCC Overall Edge
ICCC Captures Institutional Edge (2โ2 Pillars ยท 7โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immucell Corp (ICCC) driven by superior Valuation, Growth & Margin while IMMX counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, ICCC trades at N/M Forward P/E with 15.2% operating margin (+11.5% YoY revenue) versus IMMX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ICCC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IMMX sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ICCC
ICCC N/M vs IMMX N/M Fwd P/E
Growth & Margin Winner
ICCC
Op Margin 15.2% vs 0.0% ยท YoY +11.5% vs +0.0%
Momentum & Technical Winner
IMMX
1Y +88.8% vs +107.2% ยท 52W Pos 91% vs 35%
Options & Structure Winner
IMMX
UNCLASSIFIED (N/A IV) vs BREAKDOWN (17th %ile IV)
ICCC
NASDAQ
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap
$97.7M
1M Return
+6.23%
1Y Return
+88.76%
Forward P/E
N/M
Unified AI Score
43.8 / 100
HOLD
Tech 15.0
Fund 48.0
Flow 50.0
Mom 50.0
IMMX
NASDAQ
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$7.48
-4.59% 1D
Market Cap
$657.1M
1M Return
-6.27%
1Y Return
+107.2%
Forward P/E
N/M
Unified AI Score
50.3 / 100
HOLD
Tech 52.0
Fund 55.0
Flow 68.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ICCC +88.76%
IMMX +107.2%
Spread: +18.44 pp (IMMX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ICCC TTM Op. Margin: 15.2%
IMMX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICCC vs IMMX. Trailing 12-month operating profitability (ICCC 15.2% vs IMMX 0.0%) and valuation multiples (ICCC N/M vs IMMX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ICCC | IMMX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $97.7M | $657.1M | Larger Scale | IMMX |
| Trailing P/E Ratio Valuation | 56.6x | N/M | Lower Multiple | ICCC |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +11.5% | +0.0% | Higher Growth | ICCC |
| Operating Margin (TTM) Profitability | 15.2% | 0.0% | Higher Margin | ICCC |
| Net Profit Margin Profitability | 2.6% | 0.0% | Higher Margin | ICCC |
| Return on Equity (ROE) Capital Efficiency | 2.6% | -27.0% | Higher ROE | ICCC |
| 52-Week Range Position Momentum | 91% ($5โ$12) | 35% ($3โ$15) | Stronger Trend | ICCC |
| Beta / 30D Volatility Risk Regime | 0.24ฮฒ ยท 46% Vol | 1.80ฮฒ ยท 84% Vol | Lower Realized Risk | ICCC |
| Unified Institutional Score Composite Signal | 43.8 / 100 (HOLD) | 50.3 / 100 (HOLD) | Higher Composite | IMMX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ICCC vs IMMX Buy Guide
ICCC
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
IMMX
BREAKDOWN
58d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
17th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ICCC nor IMMX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.